Abstract
Objective Observational medical databases, such as electronic health records and insurance claims, track the healthcare trajectory of millions of individuals. These databases provide real-world longitudinal information on large cohorts of patients and their medication prescription history. We present an easy-to-customize framework that systematically analyzes such databases to identify new indications for on-market prescription drugs.
Materials and Methods Our framework provides an interface for defining study design parameters and extracting patient cohorts, disease-related outcomes, and potential confounders in two observational databases, covering more than 150 million patients. It then applies causal inference methodology to emulate hundreds of randomized controlled trials (RCTs) for prescribed drugs, while adjusting for confounding and selection biases. After correcting for multiple testing, it outputs the estimated effects and their statistical significance in each database.
Results We demonstrate the utility of the framework in a case study of Parkinson’s disease (PD) and evaluate the effect of 259 drugs on various PD progression measures. The results of these emulated trials reveal a remarkable agreement between the two observational medical databases for the most promising candidates.
Discussion Estimating drug effects from observational data is challenging due to data biases and noise. To tackle this challenge, we integrate causal inference methodology with domain knowledge and compare the estimated effects in two separate databases.
Conclusion Our framework enables a systematic search for drug repurposing candidates by emulating RCTs that use observational data. The high level of agreement in the results obtained in two separate databases provides an internal validation of identified effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Study was done in IBM Research.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
The data analyzed in this paper is available in (i) IBM Explorys Therapeutic Dataset and (ii) IBM MarketScan Research Databases. These data does not include information on clinical trials.